Welcome to our dedicated page for Novo Nordisk A/S news (Ticker: NVO), a resource for investors and traders seeking the latest updates and insights on Novo Nordisk A/S stock.
Novo Nordisk A/S develops, manufactures and markets medicines for serious chronic diseases, with a core franchise in diabetes care and obesity treatment. News for NVO commonly centers on GLP-1 products such as Wegovy, including FDA approvals for new formulations and indications, U.S. launch and access initiatives, and clinical data tied to weight management, cardiovascular risk factors and metabolic liver disease.
Company updates also cover investigational programs such as CagriSema, pipeline results in related therapeutic areas, patient-safety actions involving compounded semaglutide, collaborations with pharmacy or telehealth channels, and capital-allocation matters such as share repurchase activity.
Novo Nordisk (NVO) reported phase 3 STEP Young topline data showing once-weekly semaglutide plus lifestyle modification reduced BMI more than placebo in children aged 6 to under 12 years with obesity at week 68.
The primary endpoint of percentage change in BMI from baseline to week 68 was met, demonstrating superior BMI reduction versus placebo. A key secondary outcome showed that 40.4% of children receiving semaglutide were no longer classified as having obesity, compared with 0% on placebo, when both groups also followed a reduced-calorie diet and increased physical activity. At baseline, more than 85% of participants had class II or III severe obesity. The trial enrolled 165 children and used weight-based doses up to 1.7 mg or 2.4 mg. Overall safety and tolerability, including effects on growth and pubertal development, were reported as consistent with prior paediatric and adult semaglutide trials, with no new safety concerns identified.
Novo Nordisk (NYSE:NVO) reports progress on its B-share repurchase programme launched on 6 May 2026 under EU Safe Harbour rules. This sub-programme allows buybacks of up to DKK 11,200,000,010.45 through 1 February 2027, as part of an overall DKK 15 billion 12‑month programme starting 4 February 2026.
From 24–28 August 2026, Novo Nordisk repurchased 1,050,000 B shares for DKK 317,196,973, bringing accumulated repurchases under this sub-programme to 16,220,000 B shares worth DKK 4,907,673,815. As of 28 August 2026, the company has repurchased 30,979,179 B shares since 4 February 2026 at an average price of DKK 281.08, totalling DKK 8,707,673,805. Novo Nordisk now holds 45,019,876 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Novo Nordisk (NYSE:NVO) reports progress on its ongoing share repurchase programme conducted under EU Safe Harbour rules. The 12‑month programme, running from 4 February 2026, targets up to DKK 15 billion of B share buybacks. A sub-programme initiated on 6 May 2026 allows repurchases of up to DKK 11,200,000,010.45 through 1 February 2027.
Between 17–21 August 2026, Novo Nordisk bought 1,045,000 B shares at average prices around DKK 293–299, bringing accumulated repurchases under the May programme to 15,170,000 shares for DKK 4,590,476,842. As of 21 August 2026, the company has repurchased 29,929,179 B shares since 4 February 2026, for DKK 8,390,476,831 at an average price of DKK 280.34 per share. Novo Nordisk now holds 43,969,876 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Novo Nordisk (NYSE:NVO) reports progress on its share repurchase programme conducted under EU Safe Harbour rules. The 12‑month programme, running from 4 February 2026, has an expected total size of up to DKK 15 billion, including a sub‑programme initiated on 6 May 2026 to buy B shares for up to DKK 11,200,000,010.45 through 1 February 2027.
Between 10–14 August 2026, Novo Nordisk repurchased 1,000,000 B shares, bringing accumulated buybacks under the May sub‑programme to 14,125,000 shares for DKK 4,281,660,830. As of 14 August 2026, the company has repurchased 28,884,179 B shares since 4 February 2026 for DKK 8,081,660,819 at an average price of DKK 279.80. Novo Nordisk now holds 42,924,876 B treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Novo Nordisk (NYSE:NVO) provides an update on its share repurchase activity under the Safe Harbour programme initiated on 6 May 2026, which allows repurchases of B shares up to DKK 11,200,000,010.45 through 1 February 2027, as part of a broader DKK 15 billion 12‑month buyback.
From 4–7 August 2026, Novo Nordisk repurchased 820,000 B shares for DKK 246,811,452, bringing accumulated Safe Harbour purchases to 13,125,000 shares for DKK 3,980,067,920. As of 7 August 2026, it has bought 27,884,179 B shares since 4 February 2026 for DKK 7,780,067,909 and now holds 41,924,876 B shares as treasury shares, equal to 0.9% of its 4,465,000,000 total A and B shares.
Novo Nordisk (NYSE:NVO) and Amazon Web Services have entered a strategic partnership to accelerate drug discovery and modernise Novo Nordisk’s operations using agentic AI and cloud technologies. AWS is designated as Novo Nordisk’s preferred cloud provider and strategic AI partner.
The companies have established a London-based AI co-innovation hub, combining AWS engineers and AI specialists with Novo Nordisk R&D teams to shorten the path from drug target to first human dose. According to Novo Nordisk, the collaboration has already reduced clinical documentation time and enabled more than 25,000 employees to improve productivity, leveraging services such as Amazon Bio Discovery, Amazon Bedrock and Amazon Bedrock AgentCore across research and operations.
Novo Nordisk (NYSE:NVO) reported transactions in its shares by board members, executives and associated persons in line with Article 19 of the EU Market Abuse Regulation. Several directors and executive vice presidents, including the President and CEO and the CFO, had Novo Nordisk B shares vested under the Restricted Shares programme “Novo Nordisk 100th Anniversary Shares”. Each reported person received 74 shares (ISIN DK0062498333) at a reference price of DKK 294.30, corresponding to DKK 21,778.20 per individual vesting. The transactions were recorded on 5 August 2026 and took place outside a trading venue, and were notified to Novo Nordisk and disclosed as a company announcement.
Novo Nordisk (NYSE:NVO) obtained a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V. in a patent case over a compounded semaglutide nasal spray. The court found that Ceban infringed Novo Nordisk's supplementary protection certificate for semaglutide and ordered it to stop selling the nasal spray, remove product references, disclose commercial supply-chain information, and reimburse Novo Nordisk's legal costs.
According to Novo Nordisk, no nasal spray formulation of semaglutide is approved by any regulatory authority, and the company does not manufacture or endorse compounded semaglutide. Approved semaglutide medicines from Novo Nordisk include Wegovy, Ozempic and Rybelsus.
Novo Nordisk (NYSE:NVO) reported Q2 2026 net sales of DKK 78,488 million, up 3% at constant exchange rates (CER), while reported operating profit fell 16% at CER to DKK 27,061 million, impacted by prior-year US 340B rebate provision reversals and DKK 6.3 billion non-cash impairments to intangible pipeline assets, including DKK 4.0 billion for monlunabant.
Q2 2026 adjusted sales rose 7% at CER and adjusted operating profit increased 11% at CER to DKK 33,389 million, driven by GLP-1 volume growth and favourable US rebate adjustments. Wegovy pill has surpassed 5 million prescriptions in the US, with weekly prescriptions above 265,000, and has launched in the UAE and UK. EMA approved Wegovy 7.2 mg pen and Wegovy pill based on data showing up to 20.7% and 16.6% mean weight loss, respectively. The ZEUS phase 3 trial with ziltivekimab did not meet its primary endpoint. Full-year 2026 adjusted sales and adjusted operating profit growth are now guided to 0% to -6% at CER.
Novo Nordisk (NYSE:NVO) reported second-quarter 2026 adjusted sales of DKK 78,488 million, up 7% at constant exchange rates (CER), and adjusted operating profit of DKK 33,389 million, up 11% at CER. These adjusted growth rates exclude non-recurring impacts from US 340B provision reversals and DKK 6.3 billion of non-cash impairment charges related to intangible pipeline assets, including monlunabant.
For full-year 2026 at CER, Novo Nordisk now expects adjusted sales growth of 0% to -6% and adjusted operating profit growth of 0% to -6%, improved from previous ranges of -4% to -12% for both metrics. According to Novo Nordisk, the upgraded outlook is driven by increased expectations for GLP-1 product sales. On a non-adjusted basis, the mid-points of 2026 sales and operating profit growth guidance at CER would be 5% and 12%, respectively. Full financial results for the first six months of 2026 will be published on 4 August 2026.